080720 — Union Korea Pharm Co Balance Sheet
0.000.00%
HealthcareSpeculativeMicro Cap
Annual balance sheet for Union Korea Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,898 | 20,745 | 6,142 | 6,690 | 4,546 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 27,085 | 26,796 | 33,725 | 34,278 | 20,808 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 44,045 | 58,782 | 54,570 | 49,683 | 40,198 |
Net Property, Plant And Equipment | 39,996 | 43,787 | 44,613 | 34,596 | 28,659 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 97,183 | 119,044 | 112,523 | 94,425 | 74,900 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 23,026 | 44,477 | 58,992 | 59,009 | 63,949 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 28,814 | 66,703 | 63,910 | 64,101 | 66,651 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Total Equity | 68,369 | 52,341 | 48,612 | 30,324 | 8,249 |
Total Liabilities & Shareholders' Equity | 97,183 | 119,044 | 112,523 | 94,425 | 74,900 |
Total Common Shares Outstanding |